Merck Stock Soars on Strong Q2 Earnings Beat
Merck & Co., Inc.'s stock price surged after the company announced its quarterly earnings, exceeding expectations. In the quarter ended August 4, 2026, Merck reported a revenue of $16.61 billion, representing a 5.1% year-over-year increase from the prior period comparison.
The company's earnings per share (EPS) came in at -$0.13, which was better than the consensus estimate of -$0.26. However, this is largely due to acquisition-related charges that temporarily distorted the profit line. Merck's market value stands at $334.49 billion, with shares trading at $135.57 after moving up $2.65 on the session.
Analysts are watching Keytruda, the company's biggest product and a key driver of its oncology franchise. The quarter's revenue and guidance reset have made the 2026 earnings path more important than the headline quarter alone. Merck's shares have gained 28.58% year-to-date and 5.43% in the past five days.